OncLive SOSS

The Evolving Treatment Paradigm in Multiple Myeloma: Recent Updates - Episode 15

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

August 8, 2023

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai, Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB, Natalie S. Callander, MD, University of Washington Carbone Cancer Center , Alfred L. Garfall, MD, Abramson Cancer Center, Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

EP. 1: What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

EP. 2: NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

EP. 3: Induction Therapy Regimens for Transplant-Eligible NDMM

EP. 4: Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

EP. 5: Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP. 6: Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

EP. 7: Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

EP. 8: Patient Scenario: Treatment Options in MM at First Relapse

EP. 9: Factors in Selecting Therapy at First Relapse in Multiple Myeloma

EP. 10: Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

EP. 11: Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

EP. 12: Bispecifics in Multiple Myeloma: Dosing and Transition of Care

EP. 13: Combination Strategies With Bispecifics in Multiple Myeloma

EP. 14: Bispecifics in Multiple Myeloma: Adverse Event Management

EP. 15: CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

EP. 16: Multiple Myeloma: Unmet Needs and Future Directions in Care